Press Releases and Statements

“The results of this year’s Monitoring the Future survey demonstrate that prevention through education works,” Consumer Healthcare Products Association (CHPA) President and CEO Scott Melville said.

CHPA welcomed one new member to the CHPA Board of Directors today during the board’s fall meeting. Rekha Rao, general manager, North America, Colgate Oral Pharmaceuticals, Colgate-Palmolive Company, was elected to the board.

A recent study conducted by Charles River Associates, a leading global consulting firm, has quantified the savings consumers and the healthcare system receive from the over-the-counter (OTC) availability of the widely used cough suppressant dextromethorphan (DXM).

CHPA announces that Anita Brikman will join the organization in a dual role as the association’s Vice President, Communications & Public Affairs and as Executive Director of the CHPA Educational Foundation.

CHPA strongly supports the OTC Monograph System, but we believe that policy reforms could make the system more flexible, responsive, and accommodating to innovation.

Substance Abuse Treatment, Prevention, and Policy recently published a case study authored by CHPA about the association’s efforts to curb teen abuse of OTC cough medicine containing dextromethorphan.

CHPA released the following statement today in support of a Delaware law prohibiting the sale of OTC medicines containing the cough suppressant dextromethorphan (DXM) to minors.

CHPA today elected Jeff Needham as chairman of the CHPA Board of Directors at its June meeting. Needham serves as executive vice president and general manager of U.S. Consumer Healthcare for Perrigo Company plc, the nation’s largest manufacturer of OTC private label products for the store brand market.

Unlike other drugs subject to user fees, nonprescription drugs under the Monograph system are not subject to FDA approval prior to marketing. Many of these ingredients have been marketed for more than 40 years, with a long history of safe use. We must define value differently than industries subject to FDA approval prior to marketing.

CHPA is pleased to lend its strong support for the DXM Abuse Prevention Act (S. 2994), introduced into the U.S. Senate by Senators Bob Casey Jr. (D-PA) and Lisa Murkowski (R-AK).

CHPA issued the following statement following the Food and Drug Administration’s announcement of a public meeting to gather stakeholder input on the potential development of a user fee program for nonprescription monograph drugs.